Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins

Authors: Nora Zidane, Philippe Dussart, Laetitia Bremand, Hugues Bedouelle

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Dengue fever is the most important vector-borne viral disease. Four serotypes of dengue virus, DENV1 to DENV4, coexist. Infection by one serotype elicits long-lasting immunity to that serotype but not the other three. Subsequent infection by a different serotype is a risk factor for severe dengue. Domain III (ED3) of the viral envelope protein interacts with cell receptors and contains epitopes recognized by neutralizing antibodies. We determined the serotype specificity and cross-reactivity of human IgMs directed against ED3 by using a well-characterized collection of 90 DENV-infected and 89 DENV-uninfected human serums.

Methods

The recognitions between the four serotypes of ED3 and the serums were assayed with an IgM antibody-capture ELISA (MAC-ELISA) and artificial homodimeric antigens. The results were analyzed with Receiving Operator Characteristic (ROC) curves.

Results

The DENV-infected serums contained IgMs that reacted with one or several ED3 serotypes. The discrimination by ED3 between serums infected by the homotypic DENV and uninfected serums varied with the serotype in the decreasing order DENV1 > DENV2 > DENV3 > DENV4. The ED3 domain of DENV1 gave the highest discrimination between DENV-infected and DENV-uninfected serums, whatever the infecting serotype, and thus behaved like a universal ED3 domain for the detection of IgMs against DENV. Some ED3 serotypes discriminated between IgMs directed against the homotypic and heterotypic DENVs. The patterns of cross-reactivities and discriminations varied with the serotype.

Conclusions

The results should help better understand the IgM immune response and protection against DENV since ED3 is widely used as an antigen in diagnostic assays and an immunogen in vaccine candidates.
Literature
1.
2.
3.
Sabin AB: Research on dengue during World War II. Am J Trop Med Hyg. 1952, 1: 30-50.PubMed
4.
Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB: Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol. 1984, 120: 653-669.PubMed
5.
Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM: Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010, 10: 712-722.CrossRefPubMedPubMedCentral
6.
Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P, et al: An in-depth analysis of original antigenic sin in dengue virus infection. J Virol. 2011, 85: 410-421.CrossRefPubMed
7.
Chanama S, Anantapreecha S, An A, Sa-gnasang A, Kurane I, Sawanpanyalert P: Analysis of specific IgM responses in secondary dengue virus infections: levels and positive rates in comparison with primary infections. J Clin Virol. 2004, 31: 185-189.CrossRefPubMed
8.
Sa-Ngasang A, Anantapreecha S, AN A, Chanama S, Wibulwattanakij S, Pattanakul K, Sawanpanyalert P, Kurane I: Specific IgM and IgG responses in primary and secondary dengue virus infections determined by enzyme-linked immunosorbent assay. Epidemiol Infect. 2006, 134: 820-825.CrossRefPubMed
9.
Halstead SB, O’Rourke EJ: Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med. 1977, 146: 201-217.CrossRefPubMedPubMedCentral
10.
Jianmin Z, Linn ML, Bulich R, Gentry MK, Aaskov JG: Analysis of functional epitopes on the dengue 2 envelope (E) protein using monoclonal IgM antibodies. Arch Virol. 1995, 140: 899-913.CrossRefPubMed
11.
Bernardo L, Hermida L, Martin J, Alvarez M, Prado I, Lopez C, Martinez R, Rodriguez-Roche R, Zulueta A, Lazo L, et al: Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol. 2008, 153: 849-854.CrossRefPubMed
12.
Shi Y, Agematsu K, Ochs HD, Sugane K: Functional analysis of human memory B-cell subpopulations: IgD + CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol. 2003, 108: 128-137.CrossRefPubMed
13.
Velzing J, Groen J, Drouet MT, Van Amerongen G, Copra C, Osterhaus AD, Deubel V: Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine. 1999, 17: 1312-1320.CrossRefPubMed
14.
Smith KM, Nanda K, Spears CJ, Piper A, Ribeiro M, Quiles M, Briggs CM, Thomas GS, Thomas ME, Brown DT, et al: Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy. Am J Trop Med Hyg. 2012, 87: 743-753.CrossRefPubMedPubMedCentral
15.
Vorndam V, Kuno G: Laboratory diagnosis of dengue virus infections. Dengue and Dengue Hemorrhagic Fever. Edited by: Gubler DJ, Kuno G. 1997, Cambridge: CAB International, 313-333.
16.
Nawa M, Yamada KI, Takasaki T, Akatsuka T, Kurane I: Serotype-cross-reactive immunoglobulin M responses in dengue virus infections determined by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2000, 7: 774-777.PubMedPubMedCentral
17.
Shu PY, Chen LK, Chang SF, Su CL, Chien LJ, Chin C, Lin TH, Huang JH: Dengue virus serotyping based on envelope and membrane and nonstructural protein NS1 serotype-specific capture immunoglobulin M enzyme-linked immunosorbent assays. J Clin Microbiol. 2004, 42: 2489-2494.CrossRefPubMedPubMedCentral
18.
Holmes DA, Purdy DE, Chao DY, Noga AJ, Chang GJ: Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections. J Clin Microbiol. 2005, 43: 3227-3236.CrossRefPubMedPubMedCentral
19.
20.
Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, et al: Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002, 108: 717-725.CrossRefPubMedPubMedCentral
21.
Modis Y, Ogata S, Clements D, Harrison SC: A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA. 2003, 100: 6986-6991.CrossRefPubMedPubMedCentral
22.
Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, Baker TS, Kuhn RJ, Rossmann MG: Conformational changes of the flavivirus E glycoprotein. Structure. 2004, 12: 1607-1618.CrossRefPubMedPubMedCentral
23.
Modis Y, Ogata S, Clements D, Harrison SC: Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol. 2005, 79: 1223-1231.CrossRefPubMedPubMedCentral
24.
Cockburn JJ, Navarro Sanchez ME, Goncalvez AP, Zaitseva E, Stura EA, Kikuti CM, Duquerroy S, Dussart P, Chernomordik LV, Lai CJ, et al: Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J. 2012, 31: 767-779.CrossRefPubMed
25.
Volk DE, Lee YC, Li X, Thiviyanathan V, Gromowski GD, Li L, Lamb AR, Beasley DW, Barrett AD, Gorenstein DG: Solution structure of the envelope protein domain III of dengue-4 virus. Virology. 2007, 364: 147-154.CrossRefPubMedPubMedCentral
26.
Huang KC, Lee MC, Wu CW, Huang KJ, Lei HY, Cheng JW: Solution structure and neutralizing antibody binding studies of domain III of the dengue-2 virus envelope protein. Proteins. 2008, 70: 1116-1119.CrossRefPubMed
27.
Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, et al: Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008, 15: 312-317.CrossRefPubMed
28.
Simonelli L, Beltramello M, Yudina Z, Macagno A, Calzolai L, Varani L: Rapid structural characterization of human antibody-antigen complexes through experimentally validated computational docking. J Mol Biol. 2010, 396: 1491-1507.CrossRefPubMed
29.
Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA: Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure. 2012, 20: 303-314.CrossRefPubMed
30.
Midgley CM, Flanagan A, Tran HB, Dejnirattisai W, Chawansuntati K, Jumnainsong A, Wongwiwat W, Duangchinda T, Mongkolsapaya J, Grimes JM, et al: Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol. 2012, 188: 4971-4979.CrossRefPubMedPubMedCentral
31.
Elahi M, Islam MM, Noguchi K, Yohda M, Kuroda Y: High resolution crystal structure of dengue-3 envelope protein domain III suggests possible molecular mechanisms for serospecific antibody recognition. Proteins. 2013, 81: 1090-1095.CrossRefPubMed
32.
Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH: Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog. 2012, 8: e1002930-CrossRefPubMedPubMedCentral
33.
Simonelli L, Pedotti M, Beltramello M, Livoti E, Calzolai L, Sallusto F, Lanzavecchia A, Varani L: Rational engineering of a human anti-dengue antibody through experimentally validated computational docking. PLoS One. 2013, 8: e55561-CrossRefPubMedPubMedCentral
34.
Chen Y, Maguire T, Marks RM: Demonstration of binding of dengue virus envelope protein to target cells. J Virol. 1996, 70: 8765-8772.PubMedPubMedCentral
35.
Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, Deubel V, Mazie JC, Lafaye P: Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol. 2001, 82: 1885-1892.CrossRefPubMed
36.
Hung JJ, Hsieh MT, Young MJ, Kao CL, King CC, Chang W: An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol. 2004, 78: 378-388.CrossRefPubMedPubMedCentral
37.
Pattnaik P, Babu JP, Verma SK, Tak V, Rao PV: Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. J Chromatogr B Analyt Technol Biomed Life Sci. 2007, 846: 184-194.CrossRefPubMed
38.
Huerta V, Chinea G, Fleitas N, Sarria M, Sanchez J, Toledo P, Padron G: Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res. 2008, 137: 225-234.CrossRefPubMed
39.
Kaufmann B, Rossmann MG: Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect. 2011, 13: 1-9.CrossRefPubMed
40.
Watterson D, Kobe B, Young PR: Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. J Gen Virol. 2012, 93: 72-82.CrossRefPubMed
41.
Zidane N, Ould-Abeih MB, Petit-Topin I, Bedouelle H: The folded and disordered domains of human ribosomal protein SA have both idiosyncratic and shared functions as membrane receptors. Biosci Rep. 2013, 33: e00011-
42.
Jaiswal S, Khanna N, Swaminathan S: High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in escherichia coli. Protein Expr Purif. 2004, 33: 80-91.CrossRefPubMed
43.
Chin JF, Chu JJ, Ng ML: The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007, 9: 1-6.CrossRefPubMed
44.
Chavez JH, Silva JR, Amarilla AA, Moraes Figueiredo LT: Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals. 2010, 38: 613-618.CrossRefPubMed
45.
Pryor MJ, Carr JM, Hocking H, Davidson AD, Li P, Wright PJ: Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg. 2001, 65: 427-434.PubMed
46.
Lok SM, Ng ML, Aaskov J: Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J Med Virol. 2001, 65: 315-323.CrossRefPubMed
47.
Crill WD, Hughes HR, Delorey MJ, Chang GJ: Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009, 4: e4991-CrossRefPubMedPubMedCentral
48.
Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, De Silva AM: Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009, 392: 103-113.CrossRefPubMedPubMedCentral
49.
Simmons M, Porter KR, Escamilla J, Graham R, Watts DM, Eckels KH, Hayes CG: Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies. Am J Trop Med Hyg. 1998, 58: 144-151.PubMed
50.
Holbrook MR, Shope RE, Barrett AD: Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses. J Clin Microbiol. 2004, 42: 4101-4110.CrossRefPubMedPubMedCentral
51.
Batra G, Nemani SK, Tyagi P, Swaminathan S, Khanna N: Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera. BMC Infect Dis. 2011, 11: 64-CrossRefPubMedPubMedCentral
52.
Simmons M, Nelson WM, Wu SJ, Hayes CG: Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg. 1998, 58: 655-662.PubMed
53.
Zhang ZS, Yan YS, Weng YW, Huang HL, Li SQ, He S, Zhang JM: High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J Virol Methods. 2007, 143: 125-131.CrossRefPubMed
54.
Babu JP, Pattnaik P, Gupta N, Shrivastava A, Khan M, Rao PV: Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine. 2008, 26: 4655-4663.CrossRefPubMed
55.
Batra G, Raut R, Dahiya S, Kamran N, Swaminathan S, Khanna N: Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. J Virol Methods. 2010, 167: 10-16.CrossRefPubMed
56.
Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G: Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010, 9: 137-147.CrossRefPubMed
57.
Khanam S, Etemad B, Khanna N, Swaminathan S: Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg. 2006, 74: 266-277.PubMed
58.
Chen S, Yu M, Jiang T, Deng Y, Qin C, Qin E: Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 2007, 26: 361-367.CrossRefPubMed
59.
Etemad B, Batra G, Raut R, Dahiya S, Khanam S, Swaminathan S, Khanna N: An envelope domain III-based chimeric antigen produced in pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg. 2008, 79: 353-363.PubMed
60.
Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Fevrier M, Bedouelle H, Schwartz O, Despres P, Tangy F: Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis. 2007, 1: e96-CrossRefPubMedPubMedCentral
61.
Khanam S, Pilankatta R, Khanna N, Swaminathan S: An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine. 2009, 27: 6011-6021.CrossRefPubMed
62.
Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Despres P, Tangy F: Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine. 2010, 28: 6730-6739.CrossRefPubMed
63.
Danecek P, Lu W, Schein CH: PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype. J Mol Biol. 2010, 396: 550-563.CrossRefPubMed
64.
Bowen DM, Lewis JA, Lu W, Schein CH: Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four dengue serotypes. Vaccine. 2012, 30: 6081-6087.CrossRefPubMedPubMedCentral
65.
Dussart P, Baril L, Petit L, Beniguel L, Quang LC, Ly S, Azevedo Rdo S, Meynard JB, Vong S, Chartier L, et al: Clinical and virological study of dengue cases and the members of their households: the multinational DENFRAME Project. PLoS Negl Trop Dis. 2012, 6: e1482-CrossRefPubMedPubMedCentral
66.
Bedouelle H, Brient-Litzler E, Dussart P, Despres P, Bremand L: Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications. 2008, European Patent Office, EP2003144
67.
Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993, 39: 561-577.PubMed
68.
Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.CrossRefPubMed
69.
Metz CE, Herman BA, Shen JH: Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. Stat Med. 1998, 17: 1033-1053.CrossRefPubMed
70.
71.
Zidane N, Dussart P, Bremand L, Villani ME, Bedouelle H: Thermodynamic stability of domain III from the envelope protein of flaviviruses and its improvement by molecular design. Protein Eng Des Sel. 2013, 26: 389-399.CrossRefPubMed
72.
Lisova O, Hardy F, Petit V, Bedouelle H: Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol. 2007, 88: 2387-2397.CrossRefPubMed
73.
Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, et al: NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol. 2009, 183: 2610-2621.CrossRefPubMedPubMedCentral
74.
Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, Mukhopadhyay S, Baker TS, Strauss JH, Rossmann MG, Kuhn RJ: Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol. 2003, 10: 907-912.CrossRefPubMedPubMedCentral
75.
Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, De Silva AM, et al: The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010, 8: 271-283.CrossRefPubMed
76.
Gromowski GD, Barrett ND, Barrett AD: Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol. 2008, 82: 8828-8837.CrossRefPubMedPubMedCentral
77.
Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W: Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003, 69: 48-60.PubMed
78.
Konishi E, Kosugi S, Imoto J: Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine. 2006, 24: 2200-2207.CrossRefPubMed
Metadata
Title
Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins
Authors
Nora Zidane
Philippe Dussart
Laetitia Bremand
Hugues Bedouelle
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-302

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue

Research article

Cytotoxic response persists in subjects treated for tuberculosis decades ago

Research article

Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China

Erratum

Erratum to: Evaluation of the clinical value of ELISA based on MPT64 antibody aptamer for serological diagnosis of pulmonary tuberculosis

Research article

Diagnostic value of symptoms and laboratory data for pertussis in adolescent and adult patients

Research article

Age-specific contacts and travel patterns in the spatial spread of 2009 H1N1 influenza pandemic

Research article

A hospital-based matched case–control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits